文献速递胸部肿瘤

依托泊苷联合顺铂对比紫杉醇联合卡铂同步胸部放疗治疗不可切除III期非小细胞肺癌:一项多中心随机III期试验

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
PubMed 文献 · Ann Oncol · 2017-01-01

这项多中心随机III期试验比较了依托泊苷/顺铂(EP)与紫杉醇/卡铂(PC)同步胸部放疗治疗不可切除III期非小细胞肺癌的疗效。共200例患者随机分组,191例接受治疗。中位随访73个月,EP组3年总生存率显著高于PC组,估计差异为15.0%(95%CI 2.0%-28.0%,P=0.024)。EP组≥3级食管炎发生率更高,PC组≥2级放射性肺炎发生率更高。作者认为EP在总生存方面可能优于每周PC方案。

要点

  • EP组3年总生存率显著高于PC组,估计差异为15.0%(95%CI 2.0%-28.0%,P=0.024)。
  • 中位生存期EP组23.3个月 vs PC组20.7个月(log-rank检验P=0.095,HR 0.76,95%CI 0.55-1.05)。
  • PC组≥2级放射性肺炎发生率33.3% vs EP组18.9%(P=0.036);EP组≥3级食管炎发生率20.0% vs PC组6.3%(P=0.009)。

核心结论

  • 在不可切除III期非小细胞肺癌的同步放化疗中,EP方案在总生存方面可能优于每周PC方案。

研究设计与样本

  • 多中心随机III期试验,共200例患者随机分组,191例接受治疗(EP组95例,PC组96例)。
  • EP组:依托泊苷50 mg/m2第1-5天,顺铂50 mg/m2第1天和第8天,每4周重复,共2周期,同步胸部放疗60-66 Gy。
  • PC组:紫杉醇45 mg/m2和卡铂(AUC 2)第1天每周给药,同步胸部放疗60-66 Gy。
  • 主要终点为总生存期;研究设计为80%把握度检测3年OS绝对提高17%,双侧α=0.05。

主要发现

  • 中位随访73个月,EP组3年OS显著高于PC组,估计差异15.0%(95%CI 2.0%-28.0%,P=0.024)。
  • 中位生存期EP组23.3个月 vs PC组20.7个月(log-rank检验P=0.095,HR 0.76,95%CI 0.55-1.05)。
  • ≥2级放射性肺炎发生率PC组33.3% vs EP组18.9%(P=0.036)。
  • ≥3级食管炎发生率EP组20.0% vs PC组6.3%(P=0.009)。

关键数值与推荐

  • EP组:依托泊苷50 mg/m2第1-5天,顺铂50 mg/m2第1天和第8天,每4周重复,共2周期,同步胸部放疗60-66 Gy。
  • PC组:紫杉醇45 mg/m2和卡铂(AUC 2)第1天每周给药,同步胸部放疗60-66 Gy。

临床怎么用

  • 作者认为在不可切除III期非小细胞肺癌的同步放化疗中,EP方案在总生存方面可能优于每周PC方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multicenter phase III trial was conducted to compare the efficacy of concurrent thoracic radiation therapy with either etoposide/cisplatin (EP) or carboplatin/paclitaxel (PC) in patients with stage III NSCLC. PATIENTS AND METHODS: Patients were randomly received 60-66 Gy of thoracic radiation therapy concurrent with either etoposide 50 mg/m2 on days 1-5 and cisplatin 50 mg/m2 on days 1 and 8 every 4 weeks for two cycles (EP arm), or paclitaxel 45 mg/m2 and carboplatin (AUC 2) on day 1 weekly (PC arm). The primary end point was overall survival (OS). The study was designed with 80% power to detect a 17% superiority in 3-year OS with a type I error rate of 0.05. RESULTS: A total of 200 patients were randomized and 191 patients were treated (95 in the EP arm and 96 in the PC arm). With a median follow-up time of 73 months, the 3-year OS was significantly higher in the EP arm than that of the PC arm. The estimated difference was 15.0% (95% CI 2.0%-28.0%) and P value of 0.024. Median survival times were 23.3 months in the EP arm and 20.7 months in the PC arm (log-rank test P = 0.095, HR 0.76, 95%CI 0.55-1.05). The incidence of Grade ≥2 radiation pneumonitis was higher in the PC arm (33.3% versus 18.9%, P = 0.036), while the incidence of Grade ≥3 esophagitis was higher in the EP arm (20.0% versus 6.3%, P = 0.009). CONCLUSION: EP might be superior to weekly PC in terms of OS in the setting of concurrent chemoradiation for unresectable stage III NSCLC. TRIAL REGISTRATION ID: NCT01494558.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017. PMID: 28137739. doi:10.1093/annonc/mdx009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。